COMy 2024 | Manipulating the gut microbiome to change outcomes of multiple myeloma
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the role of the gut microbiome in multiple myeloma (MM). Emerging evidence links the gut microbiome to achieving measurable residual disease (MRD) negativity, resistance to the drug bortezomib, and the disease’s progression from monoclonal gammopathy of undetermined significance (MGUS) to smoldering multiple myeloma (SMM) to MM. In the future, it may be possible to manipulate the microbiome to prevent drug resistance or change the natural history of the disease. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Honoraria; Therakos/Mallinckrodt: Honoraria; Sanofi: Honoraria; JAZZ Pharmaceuticals: Honoraria; Gilead: Honoraria; Novartis: Honoraria; AstraZeneca: Honoraria; MSD: Honoraria.
